March 19, 2025
Cancer’s “Dark Matter” represents a spectrum of previously unknown proteins that have recently been identified as antigens expressed on the surface of cancer cells but not on normal cells or the thymus. Some of these dark matter proteins appear to be responsible for cancer’s malignant properties, making them valuable targets for an anti-cancer immune response. UbiVac believes DPV-001 is the first cancer immunotherapy to include cancer’s dark matter in a form that can induce a destructive anti-cancer immune response and established its therapeutic efficacy in more than a decade’ worth of preclinical studies.
November 7-10, 2024
“The still maturing median PFS we are seeing of over 9 months for PD-1 naive 1L r/m HNSCC, compares favorably with the 3.2 month median PFS reported for Keytruda monotherapy in the KN-048 study”— Rom S. Leidner, MD.
UbiVac is Pioneering the World's 1st Dark Matter Cancer Immunotherapy
UbiVac's DPV-001 Dark Matter combo Immunotherapy triples response rate and progression-free survival (PFS) over PD-1 alone for patients with r/m head and neck cancer. Data were presented at the Society for Immunotherapy of Cancer Annual Meeting November 7-10, 2024, in Houston, TX.
ASCO 2024 Dark Matter Interview with Dr. Bernard Fox American Society of Clinical Oncology, Dark Matter Interview, ASCO. June 1, 2024
An Off-the-Shelf Multivalent Vaccine Containing Cancer’s Dark Matter, DPV-001, Combined with PD-1 +/- GITR in Head & Neck Cancer: Safety, Efficacy, and Immunodynamics from the Phase 1 GITRVax Trial. These data will be presented by Rom S. Leidner, M.D., during the First-in-Human Phase I Clinical Trials Session 1 on April 8 (No. CT112, Poster Section 48, 1:30 to 5pm), at the American Association for Cancer Research Annual Meeting held 5-10 April in San Diego, CA. https://www.einpresswire.com/article/701519390/dpv-001-vaccine-containing-cancer-s-dark-matter-yields-2-to-3-fold-increased-response-rate-for-head-and-neck-cancer